ABT-089
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Attention-Deficit/Hyperactivity Disorder
Conditions
Attention-Deficit/Hyperactivity Disorder
Trial Timeline
May 1, 2008 → Oct 1, 2008
NCT ID
NCT00686933About ABT-089
ABT-089 is a phase 2 stage product being developed by AbbVie for Attention-Deficit/Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00686933. Target conditions include Attention-Deficit/Hyperactivity Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00686933 | Phase 2 | Completed |
| NCT00443391 | Phase 2 | Completed |
Competing Products
18 competing products in Attention-Deficit/Hyperactivity Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| ABT-089 + atomoxetine + placebo | AbbVie | Phase 2 | 52 |
| ABT-089 + Placebo | AbbVie | Phase 2 | 52 |
| ABT-089 + placebo | AbbVie | Phase 2 | 52 |
| MK0249 + Concerta (methylphenidate) + Placebo | Merck | Phase 2 | 52 |
| Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo | Novartis | Approved | 85 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| IR Viloxazine + Placebo | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| 100mg SPN-812 + Placebo | Supernus Pharmaceuticals | Approved | 80 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| Placebo + SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812 | Supernus Pharmaceuticals | Phase 2 | 47 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| TD-9855 + TD-9855 + Placebo | Theravance Biopharma | Phase 2 | 47 |